AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing System
23 juin 2020 09h18 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. , June 23, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio Announces Appointment of Tim Trost as Chief Financial Officer
19 mai 2020 09h00 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. , May 19, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases
22 avr. 2020 08h05 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and PARIS, April 22, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company,...
Don Haut, PhD, Joins AskBio as Chief Business Officer
07 avr. 2020 08h30 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome
18 mars 2020 09h27 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and CHAPEL HILL, N.C., March 18, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy...
Tim Kelly Joins AskBio as President of Manufacturing to Lead AAV Vector Production for Gene Therapy
12 mars 2020 09h11 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., March 12, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
CYTOO and AskBio Enter Research Agreement to Screen Gene Therapy Candidates for Rare Muscle Disorder
02 mars 2020 13h21 HE
|
Asklepios BioPharmaceutical, Inc.
GRENOBLE, France and RESEARCH TRIANGLE PARK, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- CYTOO, a leading drug discovery company on muscle disorders, today announced that it has entered into a research...
AskBio Appoints Anna Tretiakova, PhD, as Senior Vice President of Product Development
19 févr. 2020 09h18 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure
04 févr. 2020 08h05 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, and its NanoCor...
AskBio Launches AskFirst™ Patient Advocacy Program to Educate and Support Participants in Gene Therapy Clinical Trials
29 janv. 2020 10h27 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, today introduced...